References
- Hirsch M. S., D'Aquila R. T. Therapy for human immunodeficiency virus infection. N. Engl. J. Med. 1993; 328: 1686–4695
- Zimmerman T. P., Mahony W. B., Prus K. L. 3′Azido-3′-deoxythymidine an unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J. Biol. Chem. 1987; 262: 5748–5754
- Furman P. A., Fyfe J. A., St. Clair M. H., Weinhold K., Rideout J. L., Freeman G. A., Nusinoff-Lehrman S., Bolognesi D. P., Broder S., Mitsuya H., Barry D. W. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus re-verse transcriptase. Proc. Natl. Acad. Sci. USA 1986; 83: 8333–8337
- Yarchoan R., Mitsuya H., Myers C. E., Broder S. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N. Engl. J. Med. 1983; 321: 726–738
- Gogu S. R., Aggarwal S. K., Raugan S. R. S., Agrawal K. C. A pro-drug of zidovudine with enhanced efficacy against human immunodeficiency virus. Biochim. Biophys. Res. Commun. 1983; 160: 656–661
- Aggarwal S. K., Gogu S. R., Raugan S. R. S., Agrawal K. C. Synthesis and biological evaluation of pro-drugs of zidovudine. J. Med. Chem. 1990; 33: 1505–1510
- De Flora A., Benatti U., Tonetti M., Gasparini A., Giovine M., Damonte G. L., Sdraffa A. Engineered erythrocytes as carriers and bioreactors for biomedical applications. “Proceedings of the 6th European Congress of Biotechnology”, L. Alberghina, L. Frontali, P. Semi. Elsevier, Amsterdam 1994; 73–85
- Magnani M., Rossi L., Bianchi M., Cucchiarini L., Stocchi V. Reversed phase liquid chromatographic determination of 2′,3′-dideoxycytidine in human blood samples. J. Chromatogr. 1989; 491: 215–220
- Magnani M., Rossi L., Brandi G., Schiavano G. F., Montroni M., Piedimonte G. Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: In vitro and in vivo studies. Proc. Natl. Acad. Set. USA 1992; 89: 6477–6481
- Paglia D. E., Valentine W. N., Brockway R. A. Identification of thymidine nucleotidase and deoxyribonucleotidase activities among normal isozymes of 5′-nucleotidase in human erythrocytes. Proc. Natl. Acad. Sci. USA 1984; 81: 588–592
- De Flora A., Zocchi E., Guida L., Polvani C., Benatti U. Conversion of encapsulated 5-fluoro-2′-deoxyuridine 5′-monophosphate to the antineoplastic drug 5-fluoro-2′-deoxyuridine in human erythrocytes. Proc. Natl. Acad. Sci. USA 1988; 85: 3145–3149
- Magnani M., Bianchi M., Rossi L., Stocchi V. Human red blood cells as bioreactors for the release of 2′,3′-dideoxycytidine, an inhibitor of HIV infectivity. Biochem. Biophys. Res. Commun. 1985; 164: 446–452
- Fridland A., Connelly M. C., Ashmun R. Relation-ship of deoxynucleotide changes to inhibition of DNA synthesis induced by antiretroviral agent 3′-azido-3′-deoxythymidime and release of its monophosphate by human lymphoid cells (CCRFCEM). Mol. Pharmacol. 1990; 37: 665–670
- Arner E. S., Valentin A., Erikson S. Thymidine and 3′-azido-3′-2-deoxythymidine metabolism in human peripheral blood lymphocytes and monocyte-derived macrophages: A study of both anabolic and catabolic pathways. J. Biol. Chem. 1992; 267: 10968–10975
- Solimano F., Bischi G. I., Bianchi M., Rossi L., Magnani M. A nonlinear three-compartment medel for the administration of 2′,3′-dideoxycytidine by using red blood cells as bioreactors. Bull. Math. Biol. 1990; 52: 785–796